Old Web
English
Sign In
Acemap
>
authorDetail
>
Simon Hollingsworth
Simon Hollingsworth
Hoffmann-La Roche
Pharmacology
Medicine
Gastroenterology
Rash
Epidermal growth factor receptor
2
Papers
81
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
2011
Journal of Clinical Oncology
Luis Paz-Ares
Carlos Gomez-Roca
Jean-Pierre Delord
Andrés Cervantes
Benjamin Markman
Jesus Corral
Jean-Charles Soria
Yann Berge
Desamparados Roda
Fiona Russell-Yarde
Simon Hollingsworth
José Baselga
Pablo Umana
Luigi Manenti
Josep Tabernero
Show All
Source
Cite
Save
Citations (72)
Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti- EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).
2010
Journal of Clinical Oncology
Ben Markman
Carlos Gomez-Roca
Andres Cervantes-Ruiperez
Jean-Pierre Delord
L. Paz-Ares
J.C. Soria
Jesus Corral
Simon Hollingsworth
Luigi Manenti
J. Tabernero
Show All
Source
Cite
Save
Citations (9)
1